Correlates of late and very late thrombosis of drug eluting stents

American Heart Journal

Volumn 156, Issue 1, 2008, Pages 141-147

  Mishkel, Gregory J ^a,b,c   Moore, Anna L ^b   Markwell, Steve ^c   Shelton, Marc E ^a,b,c  

^a ST JOHN'S HOSPITAL   (United States)

^b Prairie Education and Research Cooperative   (United States)

^c SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

'TAXUS'; CYPHER; PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ARTICLE; BLOOD VESSEL OCCLUSION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; IMPLANTATION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEDICAL RESEARCH; PATIENT IDENTIFICATION; PERCUTANEOUS CORONARY INTERVENTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK; SMOKING; STATISTICAL SIGNIFICANCE; THROMBOSIS;

ADULT; AGE DISTRIBUTION; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; CORONARY STENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; EVALUATION STUDIES AS TOPIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROPORTIONAL HAZARDS MODELS; PROSTHESIS FAILURE; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX DISTRIBUTION; SURVIVAL RATE; TIME FACTORS;

EID: 45649085740     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.02.012     Document Type: Article

References (40)

1. Virmani R., Guagliumi G., Farb A., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious. Circulation 109 (2004) 701-705
2. McFadden E.P., Stabile E., Regar E., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 (2004) 1519-1521
3. Karvouni E., Korovesis S., and Katritsis D.G. Very late thrombosis after implantation of sirolimus eluting stent. Heart 91 (2005) e45
4. Feres F., Costa Jr. J.R., and Abizaid A. Very late thrombosis after drug-eluting stents. Catheter Cardiovasc Interv 68 (2006) 83-88
5. Ong A.T., McFadden E.P., Regar E., et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 45 (2005) 2088-2092
6. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al., BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
7. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
8. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
9. Spaulding C., Daemen J., Boersma E., et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
10. Mauri L., Hsieh W., Massaro J.M., et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
11. Iakouvou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
12. Kuchulakanti P.K., Chu W.W., Torguson R., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113 (2006) 1108-1113
13. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large, two-institutional cohort study. Lancet 369 (2007) 667-678
14. Stone G.W., Ellis S.G., Cox D.A., et al., TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
15. Moses J.W., Leon M.B., Popma J.J., et al., SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
16. Cutlip D.E., Windecker S., Mehran R., et al. Clinical endpoints in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
17. Moreno R., Ferandez C., Hernandez R., et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 45 (2005) 954-959
18. Luscher T., Steffel J., Eberli F.R., et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115 (2007) 1051-1058
19. Jaffe R., and Strauss B.H. Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives. J Am Coll Cardiol 50 (2007) 119-127
20. Airoldi F., Colombo A., Morici N., et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116 (2007) 745-754
21. Harrington R.A., and Califf R.M. Late ischemic events after clopidogrel cessation following drug-eluting stenting: should we be worried. J Am Coll Cardiol 48 (2006) 2592-2595
22. Bhatt D.L., Flather M.D., Hacke W., et al., CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49 (2007) 1982-1988
23. Steinhubl S.R., Berger P.B., Mann J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary interventions: a randomized controlled trial. JAMA 288 (2002) 2411-2420
24. Mehta S.T., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
25. Win H.K., Caldera A.E., Maresh K., et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297 (2007) 2001-2009
26. Beohar N., Davidson C.J., Kip K.K., et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 297 (2007) 1992-2000
27. Abbott J.D., Voss M.R., Nakamura M., et al. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice. Findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 50 (2007) 2029-2036
28. Levine P.H. An acute effect of cigarette smoking on platelet function. A possible link between smoking and arterial thrombosis. Circulation 48 (1973) 619-623
29. Hung J., Lam J.Y., Lacoste L., et al. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 92 (1995) 2432-2436
30. Newby D.E., Wright R.A., Labinjoh C., et al. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 99 (1999) 1411-1415
31. Ellis S.G., Colombo A., Grube E., et al. Incidence, timing, and correlates of stent thrombosis with the polymetic paclitaxel drug-eluting stent: a Taxus II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J Am Coll Cardiol 49 (2007) 1043-1051
32. Ardissino D., Mannucci P.M., Merlini P.A., et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 94 (1999) 46-51
33. Park D.W., Park S.W., Park K.Y., et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 98 (2006) 352-356
34. Spertus J.A., Kettlekamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement. Results from the PREMIER registry. Circulation 113 (2006) 2803-2809
35. Machecourt J., Danchin N., Lablanche J.M., et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and non-diabetic patients: the EVASTENT matched-cohort registry. J Am Coll Cardiol 50 (2007) 501-508
36. Vermeersch P., Agostoni P., Verheye S., et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in disease saphenous vein grafts: results from the randomized DELAYED-RRISC Trial. J Am Coll Cardiol 50 (2007) 261-277
37. Newell M.C., Henry C.R., Sigakis C.J.G., et al. Comparison of safety and efficacy of sirolimus-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction. Am J Cardiol 97 (2006) 1299-1302
38. Hoye A., Iakouvou I., Ge L., et al. Long-term outcomes after stenting of bifurcation lesions with the "crush" technique; predictors of an adverse outcome. J Am Coll Cardiol 47 (2006) 1949-1958
39. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
40. Schomig A., Dibra A., Windecker S., et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 50 (2007) 1373-1380